April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

April 23, 2025

AI Model Shows High Specificity and Sensitivity in DR Screening

Researchers urge developers for AI algorithms to monitor and publish their clinical performance for patient safety

Conexiant

April 18, 2025

Improvements in OCT Imaging Performance, Processing, and Analysis 

“We can expect instruments to continue to improve as hardware does, and image analysis techniques to improve as more powerful machine learning algorithms are introduced,” study authors wrote.

Conexiant

April 16, 2025

Biocon, Regeneron Reach Agreement on Eylea Biosimilar

The agreement clears the way for Yesafili, an FDA-approved aflibercept biosimilar, to be commercialized in the United States.

Retinal Physician

April 16, 2025

Are Vision Outcomes Affected by Race in Ranibizumab Treatment for DME?

The 24-month endpoint evaluated BCVA and ETDRS letter gains

Conexiant

April 02, 2025

GLP-1 RAs Evaluated for Long-Term Risk of NAION in Patients With Diabetes

Researchers’ subgroup analyses provide data on increased risks according to timepoint, demographics, and comorbidities.

Conexiant

April 02, 2025

Study Updates Diabetic Retinal Disease Prevalence and Incidence Data

The most recent studies on this data are at least 15 years old and do not reflect the changing landscape of treatments and technology

Conexiant

February 26, 2025

Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management